Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > ARCHIVE
ARCHIVE
- PHARMA DELEGATES
January 30, 2006
- NEW PRODUCTS
January 30, 2006
- PhRMA Announces Mr Ira Wolf as New Japan Representative
January 30, 2006
- REGULATORY NEWS IN BRIEF
January 30, 2006
- Early Approval of 4 Products Urged by Council
January 30, 2006
- JPA Prefers Sweeping but Shallow Revision of Dispensing Fees
January 23, 2006
- Replidyne Files for Approval of Faropenem in US: Daiichi Asubio
January 23, 2006
- FY2006 Medical Fee Reform Proposal Taking Shape
January 23, 2006
- Kyowa Hakko Licenses Anticancer Agent to Eli Lilly
January 23, 2006
- REPORTER'S EYE
January 23, 2006
- Meiji Seika Aims for Generic Sales of \10 Bil. by FY2008
January 23, 2006
- MEDICAL DEVICE NEWS IN BRIEF
January 23, 2006
- 40% of FD Patients Complain of Abdominal Distention
January 23, 2006
- 3 New Procedures to Be Covered by Insurance in April
January 23, 2006
- R&D NEWS IN BRIEF
January 23, 2006
- NEW PRODUCTS
January 23, 2006
- TOPICS 3 articles
January 23, 2006
- JPMA Approves FY2006 Action Plan
January 23, 2006
- Review Process Will Be Speeded Up in 2nd Half of FY2006: PMDA Director Miyajima
January 23, 2006
- SEMINAR
January 23, 2006
ページ
Japan’s pharmaceutical policy appears to be entering a new phase. The government’s newly approved honebuto policy and growth strategy both…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…